Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

1,590 questions in 129 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

current versions

No studies 281 · 17.7%Ungraded 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Neuronavigation image‐guided surgery vs standard surgery Adverse events · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma (2018) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Length of Survival · people with advanced cancer with inoperable malignant bowel obstruction (MBO) Home parenteral nutrition for people with inoperable malignant bowel obstruction (2018) · Cochrane	no estimate extracted	13 studies · 721 participants	Very low
Intervention NR Quality of life · people with advanced cancer with inoperable malignant bowel obstruction (MBO) Home parenteral nutrition for people with inoperable malignant bowel obstruction (2018) · Cochrane	no estimate extracted	3 studies · 188 participants	Very low
Intervention NR Adverse events · people with advanced cancer with inoperable malignant bowel obstruction (MBO) Home parenteral nutrition for people with inoperable malignant bowel obstruction (2018) · Cochrane	no estimate extracted	9 studies · 280 participants	Very low
Mortality with anti‐gram‐positive antibiotics vs placebo Overall mortality · febrile neutropenic patients with cancer Empirical antibiotics targeting gram‐positive bacteria for the treatment of febrile neutropenic patients… (2017) · Cochrane	RR 0.9 [0.64, 1.25]	8 studies · 1242 participants	Moderate
Treatment failure with anti‐gram‐positive antibiotics vs placebo Overall failure (disregarding modifications) · febrile neutropenic patients with cancer Empirical antibiotics targeting gram‐positive bacteria for the treatment of febrile neutropenic patients… (2017) · Cochrane	RR 1 [0.79, 1.27]	7 studies · 943 participants	Low
Treatment failure with anti‐gram‐positive antibiotics vs placebo Failure, modifications included · febrile neutropenic patients with cancer Empirical antibiotics targeting gram‐positive bacteria for the treatment of febrile neutropenic patients… (2017) · Cochrane	RR 0.72 [0.65, 0.79]	11 studies · 2169 participants	Very low
Adverse events with anti‐gram‐positive antibiotics vs placebo Any adverse events · febrile neutropenic patients with cancer Empirical antibiotics targeting gram‐positive bacteria for the treatment of febrile neutropenic patients… (2017) · Cochrane	RR 1.74 [1.5, 2.01]	9 studies · 1936 participants	Very low
Whole brain radiation therapy (WBRT) + stereotactic radiosurgery (SRS) vs WBRT Overall survival · people with brain metastases Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases (2017) · Cochrane	HR 0.82 [0.65, 1.02]	2 studies · 358 participants	Moderate
Whole brain radiation therapy (WBRT) + stereotactic radiosurgery (SRS) vs WBRT Disease‐specific survival · people with brain metastases Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases (2017) · Cochrane	RR 0.92 [0.64, 1.32]	1 study · 286 participants	Moderate
Whole brain radiation therapy (WBRT) + stereotactic radiosurgery (SRS) vs WBRT Local tumor control · people with brain metastases Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases (2017) · Cochrane	HR 0.27 [0.14, 0.52]	2 studies · 129 participants	Moderate
Whole brain radiation therapy (WBRT) + stereotactic radiosurgery (SRS) vs WBRT Functionally independent survival (KPS) · people with brain metastases Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases (2017) · Cochrane	RR 0.78 [0.61, 1]	1 study · 145 participants	Moderate
Whole brain radiation therapy (WBRT) + stereotactic radiosurgery (SRS) vs WBRT Steroid use · people with brain metastases Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases (2017) · Cochrane	RR 0.64 [0.42, 0.97]	1 study · 118 participants	Low
Heparin prophylaxis vs no prophylaxis Mortality Parenteral anticoagulation in ambulatory patients with cancer (2017) · Cochrane	RR 0.98 [0.93, 1.03]	18 studies · 9575 participants	Moderate
Heparin prophylaxis vs no prophylaxis Mortality Parenteral anticoagulation in ambulatory patients with cancer (2017) · Cochrane	RR 0.99 [0.96, 1.01]	14 studies · 5229 participants	Moderate
Heparin prophylaxis vs no prophylaxis Symptomatic VTE Parenteral anticoagulation in ambulatory patients with cancer (2017) · Cochrane	RR 0.56 [0.47, 0.68]	16 studies · 9036 participants	High
Heparin prophylaxis vs no prophylaxis Major bleeding Parenteral anticoagulation in ambulatory patients with cancer (2017) · Cochrane	RR 1.3 [0.94, 1.79]	18 studies · 9592 participants	Moderate
Heparin prophylaxis vs no prophylaxis Minor bleeding Parenteral anticoagulation in ambulatory patients with cancer (2017) · Cochrane	RR 1.7 [1.13, 2.55]	16 studies · 9245 participants	High
Heparin prophylaxis vs no prophylaxis Thrombocytopenia Parenteral anticoagulation in ambulatory patients with cancer (2017) · Cochrane	RR 0.69 [0.37, 1.27]	12 studies · 5832 participants	Moderate
Heparin prophylaxis vs no prophylaxis Quality of life impairment Parenteral anticoagulation in ambulatory patients with cancer (2017) · Cochrane	no estimate extracted	2 studies · 2241 participants	Moderate
Intervention NR Incidence of GTN (including low‐quality studies) · women with a molar pregnancy Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia (2017) · Cochrane	RR 0.37 [0.24, 0.57]	3 studies · 550 participants	Low
Intervention NR Incidence of GTN (excluding low‐quality studies) · women with a molar pregnancy Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia (2017) · Cochrane	RR 0.28 [0.1, 0.73]	1 study · 59 participants	Low
Intervention NR Time to GTN diagnosis (days) · women with a molar pregnancy Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia (2017) · Cochrane	MD 28.72 [13.19, 44.24]	2 studies · 33 participants	Low
Intervention NR Number of courses of chemotherapy to cure · women with a molar pregnancy Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia (2017) · Cochrane	MD 1.1 [0.52, 1.68]	1 study · 14 participants	Very low
Retroperitoneal drainage vs no drainage after pelvic lymphadenectomy Short‐term lymphocyst formation: both asymptomatic and symptomatic within 4 weeks after surgery · Women with gynaecological malignancies Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst… (2017) · Cochrane	RR 0.76 [0.04, 13.35]	2 studies · 204 participants	Moderate
Retroperitoneal drainage vs no drainage after pelvic lymphadenectomy Short‐term lymphocyst formation: symptomatic within 4 weeks after surgery · Women with gynaecological malignancies Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst… (2017) · Cochrane	RR 3.25 [1.26, 8.37]	2 studies · 237 participants	High
Retroperitoneal drainage vs no drainage after pelvic lymphadenectomy Short‐term lymphocyst formation: both asymptomatic and symptomatic at 8 weeks after surgery · Women with gynaecological malignancies Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst… (2017) · Cochrane	RR 0.72 [0.3, 1.71]	2 studies · 180 participants	High
Retroperitoneal drainage vs no drainage after pelvic lymphadenectomy Long‐term lymphocyst formation: both asymptomatic and symptomatic at 12 months after surgery · Women with gynaecological malignancies Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst… (2017) · Cochrane	RR 1.48 [0.89, 2.45]	1 study · 232 participants	High
Retroperitoneal drainage vs no drainage after pelvic lymphadenectomy Long‐term lymphocyst formation: symptomatic at 12 months after surgery · Women with gynaecological malignancies Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst… (2017) · Cochrane	RR 7.12 [0.89, 56.97]	1 study · 232 participants	Low
Retroperitoneal drainage vs no drainage after pelvic lymphadenectomy Febrile morbidity · Women with gynaecological malignancies Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst… (2017) · Cochrane	RR 1.76 [0.87, 3.55]	4 studies · 571 participants	High
Retroperitoneal drainage vs no drainage after pelvic lymphadenectomy Pelvic infection · Women with gynaecological malignancies Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst… (2017) · Cochrane	RR 0.42 [0.11, 1.62]	4 studies · 571 participants	Moderate
Intervention NR Overall survival · women with stage I endometrial cancer Lymphadenectomy for the management of endometrial cancer (2017) · Cochrane	HR 1.07 [0.81, 1.43]	2 studies · 1851 participants	Moderate
Intervention NR Recurrence‐free survival · women with stage I endometrial cancer Lymphadenectomy for the management of endometrial cancer (2017) · Cochrane	HR 1.23 [0.96, 1.58]	2 studies · 1851 participants	Moderate
Intervention NR Direct surgical morbidity · women with stage I endometrial cancer Lymphadenectomy for the management of endometrial cancer (2017) · Cochrane	RR 1.93 [0.79, 4.71]	2 studies · 1922 participants	Moderate
Intervention NR Surgery‐related systemic morbidity · women with stage I endometrial cancer Lymphadenectomy for the management of endometrial cancer (2017) · Cochrane	RR 3.72 [1.04, 13.27]	2 studies · 1922 participants	Moderate
Intervention NR Lymphoedema or lymphocyst · women with stage I endometrial cancer Lymphadenectomy for the management of endometrial cancer (2017) · Cochrane	RR 8.39 [4.06, 17.33]	2 studies · 1922 participants	High
Intervention NR Overall survival · people with non‐rhabdomyosarcoma soft tissue sarcoma Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma… (2017) · Cochrane	HR 1.26 [0.7, 2.29]	1 study · 83 participants	High
Intervention NR Treatment‐related mortality · people with non‐rhabdomyosarcoma soft tissue sarcoma Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma… (2017) · Cochrane	no estimate extracted	1 study · 83 participants	High
Intervention NR Disease‐free survival · people with non‐rhabdomyosarcoma soft tissue sarcoma Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma… (2017) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Progression‐free survival · people with non‐rhabdomyosarcoma soft tissue sarcoma Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma… (2017) · Cochrane	HR 1.34 [0.81, 2.2]	1 study · 83 participants	High
Intervention NR Non‐hematologic toxicity grade 3 to 4 · people with non‐rhabdomyosarcoma soft tissue sarcoma Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma… (2017) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Health‐related quality of life · people with non‐rhabdomyosarcoma soft tissue sarcoma Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma… (2017) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Occurrence of CIN2+ in histology at 18 months · women with ASCUS or LSIL Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological… (2017) · Cochrane	RR 1.5 [1.12, 2.01]	2 studies · 4028 participants	Moderate
Intervention NR Occurrence of CIN2+ in histology at 24 months · women with ASCUS or LSIL Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological… (2017) · Cochrane	RR 1.14 [0.66, 1.97]	3 studies · 4331 participants	Low
Intervention NR Occurrence of CIN3+ in histology at 18 months · women with ASCUS or LSIL Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological… (2017) · Cochrane	RR 1.24 [0.77, 1.98]	2 studies · 4028 participants	Moderate
Intervention NR Occurrence of CIN3+ in histology at 24 months · women with ASCUS or LSIL Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological… (2017) · Cochrane	RR 1.02 [0.53, 1.97]	3 studies · 4331 participants	Low
Intervention NR Occurrence of any CIN in histology at 24 months · women with ASCUS or LSIL Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological… (2017) · Cochrane	RR 2.02 [1.33, 3.08]	2 studies · 656 participants	Low
Intervention NR Default rates at 6 months · women with ASCUS or LSIL Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological… (2017) · Cochrane	RR 3.85 [1.27, 11.63]	3 studies · 5117 participants	Moderate
Intervention NR Default rates at 12 months · women with ASCUS or LSIL Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological… (2017) · Cochrane	RR 6.6	3 studies · 5115 participants	Moderate
Intervention NR Number of participants who experienced prolonged vaginal discharge · Women undergoing excision of the cervical transformation zone for cervical neoplasia Antibiotics for infection prevention after excision of the cervical transformation zone (2017) · Cochrane	RR 1.29 [0.72, 2.31]	1 study · 348 participants	Low